Published onVaccine News
The original hepatitis B vaccine, manufactured in the 1980s, was the first vaccine to prevent human cancer. Liver cancer, which the hepatitis B virus can cause, is the second leading cause of cancer deaths throughout the world, and half of these are from hepatitis B.
Now, a more effective and more practical version of that vaccine is available for adults. HEPLISAV-B™ was recently licensed and recommended for use in adults 18 years of age and older. Previous hepatitis B vaccines required three doses over a six-month span. Since the new vaccine requires just two doses, public health officials hope more adults will begin and complete hepatitis B vaccination. Currently, approximately 1 of 4 U.S. adults are vaccinated against hepatitis B.
In this video, Dr. Offit talks about the vaccine technology advancements used to make the improved hepatitis B vaccines for adults. These include the advent of a new adjuvant that evokes a stronger immune response and delivers better protection.
Materials in this section are updated as new information and vaccines become available. The Vaccine Education Center staff regularly reviews materials for accuracy.
You should not consider the information in this site to be specific, professional medical advice for your personal health or for your family's personal health. You should not use it to replace any relationship with a physician or other qualified healthcare professional. For medical concerns, including decisions about vaccinations, medications and other treatments, you should always consult your physician or, in serious cases, seek immediate assistance from emergency personnel.